Jianliang Yang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College

发表论文 122 篇 · 总被引 1603 次 · h-index 21

代表论文

• Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018) (2022 · Cancer Pathogenesis and Therapy · 被引 25)
• Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study (2024 · Journal of Hematology & Oncology · 被引 16)
• First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China (2022 · International Journal of Radiation Oncology*Biology*Physics · 被引 15)
• Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients (2024 · Cancer Immunology Immunotherapy · 被引 12)
• Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era (2022 · BMC Cancer · 被引 12)
• High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer (2024 · Molecular & Cellular Proteomics · 被引 10)